Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (≥20–30% blasts) and now me...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Formato: Artigo
Idioma:Inglês
Publicado: Cancer Intelligence 2008
Assuntos:
Short Communications
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3234073/
https://ncbi.nlm.nih.gov/pubmed/22275991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2008.121
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares